Idiopathic Membranous Nephropathy (IMN) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032
Membranous nephropathy (MN), also known as membranous glomerulonephritis, is a chronic glomerular disease characterized by specific morphological features observed through light, immunofluorescence (IF), and electron microscopy (EM) analysis of renal tissue. These features include thickening the glomerular basement membrane (GBM) and GBM spikes. Immunostaining reveals granular deposits of IgG and complement along the periphery of glomerular capillary loops, while electron microscopy shows electron-dense subepithelial deposits corresponding to the observed granular IgG staining. MN can be classified into idiopathic or primary MN (IMN or PMN) when secondary factors cannot be identified. IMN, the primary form of MN, is believed to be mediated by IgG antibodies that target podocytes, with IgG4 being the predominant subclass. Several podocyte auto-antigens have been identified in adult IMN, including the M-type receptor for secretory phospholipase A2 (PLA2R1), thrombospondin type-1 domain-containing 7A (THSD7A), and neural epidermal growth factor-like 1 protein (NELL-1). These antigens account for approximately 70–80%, 3–5%, and 5–10% of IMN cases. Recurrence of IMN is observed in approximately half of kidney allograft recipients, resulting in graft dysfunction and failure.
· In the United States, the annual incidence of Membranous Nephropathy is 12 cases per 1 million population.
Thelansis’s “Idiopathic Membranous Nephropathy (IMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Membranous Nephropathy (IMN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Idiopathic Membranous Nephropathy (IMN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Idiopathic Membranous Nephropathy (IMN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
